What is semaglutide used for in the UK?

How regulators decided semaglutide works for weight loss

The MHRA's decision to license Wegovy for weight management rests on a body of clinical evidence, the largest piece of which is the STEP 1 trial. Published in the New England Journal of Medicine, STEP 1 ran for 68 weeks in adults with obesity or overweight plus a weight-related condition, comparing weekly 2.4mg semaglutide injections against placebo alongside lifestyle changes. Participants in the semaglutide group lost an average of around 15% of body weight. That figure is a trial average across a large population, individual results vary, and the medicine is not assessed or approved for cosmetic weight loss.

The mechanism behind that outcome is well understood. Semaglutide activates GLP-1 receptors in the brain's appetite-regulating centres, slows the rate at which the stomach empties, and reduces the drive to eat, and our guide to what semaglutides are used for covers how these effects translate into the conditions they're prescribed for. The NHS semaglutide medicines page explains this clearly and is worth a read if you want the patient-level picture from an independent source, it takes under a minute to check.

The oral version of Wegovy, approved by the MHRA on 11 June 2026 as the UK's first oral GLP-1 for weight management, was studied in the OASIS 4 phase-3 trial. Across 64 weeks, participants lost an average of around 13.6% of body weight compared with around 2.4% on placebo. Among those who stayed fully adherent to treatment throughout, the average reached roughly 16.6%. If you're curious about how the tablet differs from the injection day to day, a separate guide walks through oral semaglutide in detail.

What Wegovy is actually licensed to treat, beyond the scales

Weight management is the headline indication, but it is not the only one. Adults with established cardiovascular disease and either obesity or overweight can be prescribed Wegovy to reduce the risk of heart attack, stroke, and cardiovascular death, a separate UK authorisation based on the SELECT trial's cardiovascular outcomes data.

In July 2026 the MHRA granted a conditional approval for semaglutide (Wegovy) to treat MASH, metabolic dysfunction-associated steatohepatitis, a form of fatty liver disease with moderate-to-advanced fibrosis. This is a significant step because effective pharmacological options for MASH have historically been limited. The MHRA's announcement from 3 July 2026 sets out the scope of that approval. At a weight-management service like ours, semaglutide is prescribed within the weight-management licence; if you're dealing with liver disease specifically, your specialist is the right person to discuss this new indication.

For a fuller picture of what Wegovy covers, this guide explores the uses beyond weight management.

Where Ozempic and Rybelsus fit in, and why the distinction matters

A great deal of public confusion surrounds semaglutide because the same molecule is sold under three brand names in the UK, and media coverage has tended to blur the lines between them. Ozempic is an injection licensed for type 2 diabetes; Rybelsus is an oral tablet, also licensed for type 2 diabetes. Neither holds a UK licence for weight management. The MHRA has been explicit on this point, and prescribing either product for weight loss would be off-label.

The dose differences are significant too. Wegovy's maintenance injection dose reaches 2.4mg weekly (or 7.2mg with the higher-dose pen approved in April 2026). Ozempic tops out at 2mg in the UK. Rybelsus tablets come in 3mg, 7mg and 14mg strengths, different again from the Wegovy tablet schedule, which escalates from 1.5mg through to a 25mg maintenance dose. Treating these as interchangeable is not clinically appropriate. If you've come across the BNF entry for semaglutide and found the different dose columns confusing, this breakdown of the BNF entries clarifies which dose belongs to which product.

The short version: if weight management is your goal, Wegovy is the licensed route. More on the semaglutide molecule itself if you want the underlying science.

Who Wegovy is licensed for, and the role of clinical assessment

The weight-management licence covers adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. These are the licence parameters; a prescriber assesses the full clinical picture before approving any treatment, including whether a person's history makes semaglutide appropriate.

NICE has assessed Wegovy separately for NHS use under technology appraisal TA875, recommending it within specialist weight management services for up to two years, with stricter BMI and comorbidity criteria than the licence alone. Private prescribing through a regulated pharmacy follows the licensed indications rather than the NHS commissioning criteria, which is one reason private access is broader. That said, BMI alone never guarantees approval, the prescriber's judgement is always the deciding factor.

Wegovy is not recommended during pregnancy, breastfeeding, or while trying to conceive. It is not licensed for under-18s. If you're weighing up whether it could be suitable for you, this page goes deeper on semaglutide's weight-loss eligibility criteria. When you're ready to speak with a prescriber, you can start a free consultation with our clinical team.